INDOCO

Feb 3 (Reuters) - Indoco Remedies Ltd INRM.NS:

• INDOCO REMEDIES LTD - DEC-QUARTER CONSOL NET LOSS 297.9 MILLION RUPEES

• INDOCO REMEDIES LTD - DEC-QUARTER CONSOL TOTAL INCOME FROM OPERATIONS 4.45 BILLION RUPEES

Source text: [ID:]

Further company coverage: INRM.NS

(([email protected];;))

Jan 30 (Reuters) - Indoco Remedies Ltd INRM.NS:

• INDOCO REMEDIES LTD - RECEIVES FINAL ANDA APPROVAL FOR LACOSAMIDE ORAL SOLUTION

Source text: ID:nBSEFvfNf

Further company coverage: INRM.NS

(([email protected];;))

Dec 11 (Reuters) - Indoco Remedies Ltd INRM.NS:

• RECEIVES EIR FROM USFDA FOR API FACILITY

• SUCCESSFUL INSPECTION OF FACILITY IN SEPTEMBER 2025

Source text: ID:nBSE7Dpkn3

Further company coverage: INRM.NS

(([email protected];))

Sept 19 (Reuters) - Indoco Remedies Ltd INRM.NS:

• USFDA COMPLETES INSPECTION AT INDOCO'S API FACILITY WITH ZERO OBSERVATIONS

• USFDA COMPLETED INSPECTION OF API FACILITY AT PATALGANGA

Source text: ID:nBSE4wlZgZ

Further company coverage: INRM.NS

(([email protected];;))

July 24 (Reuters) - Indoco Remedies Ltd INRM.NS:

• JUNE-QUARTER CONSOL NET LOSS 357.9 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 4.29 BILLION RUPEES

Source text: ID:nBSE1Ncwkn

Further company coverage: INRM.NS

(([email protected];;))

** Shares of Indoco Remedies INRM.NS gains 7.4% to 278 rupees, their highest since Feb. 10

** Pharma co's UK unit launches Ticagrelor film-coated tablets - used for treating patients vulnerable to heart attacks, stroke, other hearts diseases - in the UK

** More than 198,500 shares traded, nearly three times the 30-day avg

** Stock down 22% YTD

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

** India's Indoco Remedies INRM.NS up 2% at 247.56 rupees

** Co gets approval from U.S. Food and Drug Administration (FDA) for Allopurinol tablets, used to prevent or lower uric acid levels in the blood

** Approval to be positive for growth in the U.S. market, says co

** Including session's gains, stock trims 12-month decline to 20.6%

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

** Indoco Remedies INRM.NS slips as much as 6.4% to 216.07 rupees

** Pharma co's clinical research organisation AnaCipher completes 5-day comprehensive U.S. Food and Drug Administration (FDA) inspection

** Facility gets Form 483 - a notice of violations or issues found in co's practices or products, indicating non-compliance with regulations

** Co did not specify the issues found

** INRM last down 3.5%, extending YTD losses to 30.5%

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

March 10 (Reuters) - Indoco Remedies Ltd INRM.NS:

• ANACIPHER COMPLETES US FDA INSPECTION

• FACILITY RECEIVED ONE FORM 483 AT END OF INSPECTION

Source text: ID:nBSE5XTyjs

Further company coverage: INRM.NS

(([email protected];;))

Feb 12 (Reuters) - Indoco Remedies Ltd INRM.NS:

• GETS NOTICE FOR POTENTIAL TAX DEMAND OF 85 MILLION RUPEES

Source text: ID:nBSE34Vz9y

Further company coverage: INRM.NS

(([email protected];;))

** Shares of pharmaceutical co Indoco Remedies Ltd INRM.NS fall ~11% to 304 rupees, set for biggest one-day pct decline since January 2023

** Prabhudas Lilladher downgrades stock to 'hold' from 'accumulate', raises PT slightly to 325 rupees from 320 rupees

** Brokerage says Q3 U.S. sales were impacted by warning letter from FDA for a manufacturing plant in Goa

** Says, FY26 and FY27 margins to be hit by lower sales across regulated markets and ongoing remediation costs in relation to the letter

** INRM's headcount and repair & maintenance expenses will remain elevated - brokerage

** Cuts FY26 EPS estimate by 74.3% to 3.2 rupees and FY27 EPS estimate by 23.5% to 12.5 rupees

** Stock rated 'hold' on avg by 3 analysts, with median PT at 325 rupees- LSEG data

** Stock down 17.5% in last 12 months

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

Jan 21 (Reuters) - Indoco Remedies Ltd INRM.NS:

• DEC-QUARTER CONSOL NET LOSS 263.9 MILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.02 BILLION RUPEES

Source text: ID:nBSEv9z6N

Further company coverage: INRM.NS

(([email protected];;))

** Indoco Rememdies INRM.NS plunges as much as ~8.4% in biggest pct decline since Jan. 23

** Pharma firm's Goa facility gets US FDA warning letter, identifying "significant violations" of federal requirements

** Co says it will continue supply from Goa facility while working with FDA to improve compliance

** In May 2023, same facility got Official Action Indicated status, indicating it was not in compliance

** In October this year, INRM said it will have remedial action plan in place by year-end

** More than 800,000 shares traded, 4.5x the 30 day avg

** Stock last down 1.19%, trims YTD losses to ~16%

(Reporting by Ananta Agarwal in Bengaluru)

(([email protected]))

Dec 3 (Reuters) - Indoco Remedies Ltd INRM.NS:

• GOT TAX ORDER WITH POTENTIAL DEMAND OF 155.1 MILLION RUPEES

Source text: ID:nBSE83vkj6

Further company coverage: INRM.NS

(([email protected];;))

Dec 2 (Reuters) - Indoco Remedies Ltd INRM.NS:

• ANNOUNCES STRATEGIC DISTRIBUTION PARTNERSHIP WITH CLARITY PHARMA, UK

• WILL LAUNCH AROUND 20 PRODUCTS OVER NEXT 18 MONTHS THROUGH CLARITY PHARMA

• WILL LAUNCH AROUND 20 PRODUCTS OVER 18 MONTHS THROUGH CLARITY PHARMA IN UK

• WILL CONTINUE TO SUPPLY ALL PRODUCTS UNDER EXISTING B2B PARTNERSHIP TO CLIENTS

Source text: ID:nBSE6S0M60

Further company coverage: INRM.NS

(([email protected];;))

** Shares of Indoco Remedies INRM.NS rise as much as 5% to 317.50 rupees

** Co gets U.S. FDA approval for varenicline tablets, which are used to help quit smoking

** INRM last up about 2%, set to snap nine-session losing streak

** Stock still down ~22% so far this year, on track for third straight year of losses

** YTD, peers Pfizer Ltd PFIZ.NS and Ajanta Pharma AJPH.NS up ~20% and ~43%, respectively

(Reporting by Dimpal Gulwani in Bengaluru)

(([email protected]))

** Shares of Indoco Remedies INRM.NS drop ~4% to 308.25 rupees; set for sixth straight session of losses

** Drugmaker reports Q2 consol loss of 95.7 mln rupees ($1.1 mln) vs profit of 350.8 mln rupees a year ago

** Says supply constraints hurt performance of its international formulations business

** Trading volume at 3x the 30-day avg

** INRM down ~23% YTD

($1 = 84.0430 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

Oct 11 (Reuters) - Indoco Remedies Ltd INRM.NS:

• USFDA DETERMINS INSPECTION CLASSIFICATION OF GOA FACILITY OFFICIAL ACTION INDICATED

Source text for Eikon: ID:nBSE5wncb0

Further company coverage: INRM.NS

(([email protected];;))

Oct 4 (Reuters) - Indoco Remedies Ltd INRM.NS:

• FINAL ANDA APPROVAL FROM THE USFDA FOR CETIRIZINE HYDROCHLORIDE TABLETS USP, 10 MG (OTC)

Source text for Eikon: ID:nBSE4Rg7Jk

Further company coverage: INRM.NS

(([email protected];;))

Aug 21 (Reuters) - Indoco Remedies Ltd INRM.NS:

• INDOCO REMEDIES LTD - RECEIVES FINAL ANDA APPROVAL FROM USFDA FOR LOFEXIDINE TABLETS

• INDOCO REMEDIES - ANDA APPROVAL FOR LOFEXIDINE TABLETS WITH COMPETITIVE GENERIC THERAPY DESIGNATION

Source text for Eikon: ID:nBSE6S1J8Q

Further company coverage: INRM.NS

(([email protected];))

July 23 (Reuters) - Indoco Remedies Ltd INRM.NS:

• JUNE-QUARTER CONSOL NET PROFIT 26.2 MILLION RUPEES

• JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 4.24 BILLION RUPEES

Source text for Eikon: ID:nBSE92PYtL

Further company coverage: INRM.NS

(([email protected];))

June 6 (Reuters) - Indoco Remedies Ltd INRM.NS:

• RECEIVES TENTATIVE ANDA APPROVAL FROM USFDA FORCANAGLIFLOZIN AND METFORMIN HYDROCHLORIDE TABLETS

Further company coverage: INRM.NS

(([email protected];))

May 21 (Reuters) - Indoco Remedies Ltd INRM.NS:

• INDOCO REMEDIES LTD - RECEIVES FINAL ANDA APPROVAL FROM USFDA FOR PREGABALIN CAPSULES

• INDOCO REMEDIES LTD - PREGABALIN CAPSULES WILL BE MANUFACTURED BY CO AT GOA

Source text for Eikon: ID:nBSEbsFHD4

Further company coverage: INRM.NS

(([email protected];))

** Shares of pharmaceuticals company Indoco Remedies INRM.NS fall 2% to 321 rupees

** Co reports a 12% fall in Q4 net profit as costs surge

** Stock opened 1.2% higher ahead of the results, and rose as much as 2.24%

** INRM trading below its 100-day and 200-day simple moving averages since mid-April

** Stock down 2.7% so far in May, eyes fifth consecutive session of falls

($1 = 83.4975 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

March 25 (Reuters) - Indoco Remedies Ltd INRM.NS:

• UNIT WARREN REMEDIES COMMENCED COMMERCIAL PRODUCTION FROM AURANGABAD MANUFACTURING FACILITY

• UNIT COMMENCES COMMERCIAL PRODUCTION OF PHARMACEUTICAL INTERMEDIATES

Source text for Eikon: ID:nBSE553kkm

Further company coverage: INRM.NS

(([email protected];))

Jan 23 (Reuters) - Indoco Remedies Ltd INRM.NS:

• DEC-QUARTER CONSOL NET PROFIT 163 MILLION RUPEES VERSUS PROFIT 281.5 MILLION RUPEES

• DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 4.59 BILLION RUPEES VERSUS 4.11 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: INRM.NS

(([email protected];))

Dec 6 (Reuters) - Indoco Remedies Ltd INRM.NS:

• RECEIVES TENTATIVE ANDA APPROVAL FROM USFDA FOR CANAGLIFLOZIN TABLETS

Source text for Eikon: ID:nBSE7b2Tsc

Further company coverage: INRM.NS

(([email protected];;))

Oct 19 (Reuters) - Indoco Remedies Ltd INRM.NS:

• APPROVED ISSUANCE OF CORPORATE GUARANTEE OF 170 MILLION RUPEES IN FAVOUR OF CITIBANK N.A

Source text for Eikon: [ID:]

Further company coverage: INRM.NS

(([email protected];))

Sept 7 (Reuters) - Indoco Remedies Ltd INRM.NS:

• AMOUNT OF LOSS DUE TO FIRE AT AURANGABAD PLANT IS ABOUT 78.6 MILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: INRM.NS

(([email protected];))

Aug 28 (Reuters) - Indoco Remedies Ltd INRM.NS:

• AMOUNT OF LOSS DUE TO JULY 29 FIRE IS APPROXIMATELY 78.6 MILLION RUPEES

Source text for Eikon: ID:nBSE7NdcXx

Further company coverage: INRM.NS

(([email protected];))